Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.

[1]  Xubao Liu,et al.  Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: A comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  K. Matsuo,et al.  Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately , 2019, Annals of surgical oncology.

[3]  H. Sorbye,et al.  Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. , 2019, Endocrine-related cancer.

[4]  Jean-David Fumet,et al.  Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors , 2018, AntiCancer Research.

[5]  R. Baum,et al.  Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients , 2018, The Journal of Nuclear Medicine.

[6]  elliot k fishman,et al.  The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  E. Raymond,et al.  Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms , 2018, Neuroendocrinology.

[8]  Gang Li,et al.  The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma , 2018, World Journal of Surgery.

[9]  H. Sorbye,et al.  Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  H. Sorbye,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy , 2017, Neuroendocrinology.

[11]  L. Antonuzzo,et al.  Everolimus in Pancreatic Neuroendocrine Carcinomas G3 , 2017, Pancreas.

[12]  Zongguang Zhou,et al.  Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience , 2016, BMC Gastroenterology.

[13]  A. Scarpa,et al.  Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. , 2016, Surgery.

[14]  H. Sorbye,et al.  ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas , 2016, Neuroendocrinology.

[15]  G. Mai,et al.  Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems , 2015, Medicine.

[16]  Olca Basturk,et al.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas , 2015, Clinical Cancer Research.

[17]  C. Chougnet,et al.  Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. , 2015, Endocrine-related cancer.

[18]  M. Falconi,et al.  Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases , 2015, Neuroendocrinology.

[19]  A. Krasinskas,et al.  The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms , 2015, The American journal of surgical pathology.

[20]  J. Werner,et al.  Outcome of surgery for pancreatic neuroendocrine neoplasms , 2014, The British journal of surgery.

[21]  J. Furuse,et al.  Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system , 2014, Cancer science.

[22]  Ken Kato,et al.  Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. , 2014, Anticancer research.

[23]  D. Planchard,et al.  Are G3 ENETS neuroendocrine neoplasms heterogeneous? , 2013, Endocrine-related cancer.

[24]  J. Gong,et al.  Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas , 2013, Medical Oncology.

[25]  R. Riechelmann,et al.  Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas , 2013, Rare tumors.

[26]  M. Fakih,et al.  First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. , 2011, Anticancer research.

[27]  Ken Kato,et al.  Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma , 2011, Gastric Cancer.

[28]  H. Ueno,et al.  Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. , 2010, Japanese journal of clinical oncology.

[29]  B. Kos-Kudła,et al.  Capecitabine and temozolomide combination for treatment of high-grade well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma. Retrospective analysis. , 2019, Endokrynologia Polska.

[30]  H. Sorbye,et al.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  E. Raymond,et al.  Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? , 2009, Surgery.